Copper Deficiency Can Steal Your Vision — And Most Doctors Are Missing It

Copper deficiency is an emerging but underdiagnosed cause of neurological damage in adults, and this 2025 review by Leslie Klevay at the University of North Dakota draws attention to a particularly overlooked consequence: vision loss. By aggregating roughly a dozen scattered clinical case reports published across gastroenterology, hematology, and neurology journals, the review establishes that copper-deficient optic neuropathy is a real and potentially reversible condition that the ophthalmology community has largely missed.

The clinical picture varies across reported cases but consistently involves optic nerve damage. Presentations have included acute bilateral blindness, progressive vision loss over years, reduced visual acuity, night blindness in children with low blood and hair copper, and progressive optic neuropathy. The most compelling case describes a woman whose vision improved dramatically from 20/400 to 20/25 over 10 months of copper replacement therapy — an outcome the author considers too substantial to attribute to measurement error or spontaneous remission. The proposed biological mechanism is demyelination: myelination of optic nerves is a copper-dependent process, and animal studies confirm reduced myelination in copper-deficient subjects.

Copper deficiency neuropathy more broadly is now recognized as a serious, increasingly common condition that mimics subacute combined degeneration from vitamin B12 deficiency (pernicious anemia). Single clinics have reported 10–15 cases, and poor balance is the most frequent complaint. Common contributing causes include bariatric or gastrointestinal surgery, excessive zinc supplementation (zinc competitively inhibits copper absorption), dental adhesives containing zinc, hemochromatosis, lead poisoning, and malabsorption syndromes. Importantly, at least 25% of U.S. and Canadian adults consume copper below the estimated average requirement, suggesting dietary insufficiency alone may be an underappreciated driver.

Diagnostic testing carries important caveats. Serum or plasma copper is relatively insensitive because it can be falsely elevated by inflammation (C-reactive protein elevation inflates serum copper with correlation coefficients up to 0.79 in nine studies). Animal data further show that plasma copper can appear normal even when liver and organ copper stores are depleted. Erythrocyte superoxide dismutase (SOD) is identified as the most sensitive practical marker of deficiency, followed by enzymatic ceruloplasmin, serum copper, and immunoreactive ceruloplasmin. Liver copper remains the gold-standard index of copper nutriture.

For treatment, copper gluconate is the only copper supplement listed by the U.S. Pharmacopeial Convention and is the preferred form. Cupric oxide, found in many multivitamin-mineral supplements, is poorly utilized and should be avoided. Effective supplemental doses in depletion-repletion studies ranged from 2–6 mg elemental copper daily, with 4–6 mg recommended when intestinal absorption is compromised by surgery. The Tolerable Upper Intake Level of 10 mg/day does not apply to medically supervised patients. Neurological recovery is often slow and incomplete, likely reflecting slow nerve remyelination, so long-term therapy is necessary. The author also raises the intriguing possibility that the vision benefits observed in the Age-Related Macular Degeneration supplementation trials (AREDS) — which included copper alongside zinc — may have been partly or wholly attributable to the copper component.